Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant chemotherapy for pineal region tumors.

Journal of neuro-oncology·2026
Same author

Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma.

Neuro-oncology·2026
Same author

Silent Verb Generation during fMRI Reveals Post-Radiotherapy Alterations in Cerebellar-Cerebral Language Regions in Patients Treated for Medulloblastoma.

Research square·2026
Same author

A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma.

Cancer research·2026
Same author

Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors.

Science advances·2026
Same author

PHIP suppresses NuRD to enable the growth of SWI/SNF-mutant cancers.

Nature communications·2026

Related Experiment Video

Updated: Jun 1, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

Medulloblastoma: advances and challenges.

Martine F Roussel, Giles Robinson

    F1000 Biology Reports
    |June 10, 2011
    PubMed
    Summary

    Pediatric medulloblastoma treatment can be improved by understanding its molecular subtypes. Tailoring therapies to specific subtypes offers potential for reduced toxicity and better outcomes in children.

    Area of Science:

    • Pediatric neuro-oncology
    • Cancer genomics
    • Molecular pathology

    Background:

    • Medulloblastoma is the most common pediatric malignant brain tumor, often originating in the posterior fossa.
    • While many average-risk patients are cured, treatment side effects significantly impact quality of life.
    • Recent molecular and genomic studies reveal medulloblastoma's heterogeneity, with distinct subtypes.

    Purpose of the Study:

    • To highlight the need for subtype-specific therapies in medulloblastoma.
    • To emphasize the potential for reducing treatment toxicity in good-prognosis subtypes.
    • To underscore the importance of molecular understanding for improving outcomes in poor-prognosis subtypes.

    Main Methods:

    • Review of recent molecular and genomic studies on medulloblastoma.

    More Related Videos

    Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
    05:10

    Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

    Published on: October 3, 2010

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
    06:32

    Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

    Published on: September 1, 2010

    Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
    05:10

    Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

    Published on: October 3, 2010

  • Analysis of subtype-specific treatment responses.
  • Discussion of the role of risk stratification in current treatment paradigms.

    • Main Results:

    • Medulloblastoma is not a single disease but comprises distinct molecular subtypes.
    • Therapeutic response appears to be specific to these molecular subtypes.
    • Current risk stratification largely ignores these newly defined subtypes.

    Conclusions:

    • Understanding medulloblastoma molecular subgroups is critical for refining treatment strategies.
    • Developing accurate mouse models that recapitulate tumor subtypes is essential.
    • Personalized therapy based on molecular subtypes holds promise for reducing toxicity and improving cure rates.